<?xml version="1.0" encoding="UTF-8"?>
<p>An innovative compound, ACH-806 (GS 9132) is characterized as antiviral agent against HCV by using HCV replicon system. ACH-806 was discovered by using HCV replicon cells [
 <xref ref-type="bibr" rid="B35">35</xref>]. Mechanism of action studies have exposed that ACH-806 averts the apposite pattern of replication complexes by sharply binding to NS4A [
 <xref ref-type="bibr" rid="B35">35</xref>]. Moreover, ACH-806 has been inveterated to decelerate HCV replication in genotype 1 HCV infected patients in clinical trial, while the reversible nephrotoxicity prohibits its additional clinical progress [
 <xref ref-type="bibr" rid="B36">36</xref>].
</p>
